Advertisement
Friday, Aug 19, 2022
Outlook.com
Outlook.com

Biological E Aims To Produce 100 Mn Doses/Month Of Corbevax From Feb 2022

Corbevax has completed two Phase III clinical trials involving more than 3000 subjects between the ages of 18 and 80 at 33 study sites across India.

Biological E Aims To Produce 100 Mn Doses/Month Of Corbevax From Feb 2022
A nurse preparing a dose of the covid vaccination. | AP Photo/Rafiq Maqbool
Biological E Aims To Produce 100 Mn Doses/Month Of Corbevax From Feb 2022
outlookindia.com
2021-12-28T22:16:04+05:30

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100  million doses per month from February 2022 which will enable the city-based company to deliver 300 Million doses as promised to the Centre, BE said on Tuesday.       

Corbevax , India's first indigenously developed protein sub-unit vaccine against the virus, received the approval from the Drugs Controller General of India (DGCI) today, it said. According to a press release issued by the vaccine maker soon, the company plans to deliver more than one billion additional doses globally.      

"Biological E. Limited plans to complete production at a rate of 75 Million doses per month, anticipating over 100  million doses per month from February 2022. These capacities will enable the Hyderabad-based company to deliver 300 Million doses as promised to the Government of India," it said. The vaccine has been developed by Biological E. Limited in collaboration with Texas Children's Hospital Centre for Vaccine Development (Texas Children’s CVD) and Baylor College of Medicine (Baylor) in Houston, Texas.      

Mahima Datla, Managing Director, BE limited said, "Over the years, we have worked to make quality vaccines and pharmaceutical products accessible to families around the world. With this as our backdrop, we resolved to develop an affordable and effective COVID-19 vaccine. It has now become a reality. Corbevax has completed two Phase III clinical trials involving more than 3000 subjects between the ages of 18 and 80 at 33 study sites across India. The vaccine was found to be safe, well tolerated and immunogenic, the company said.       

In the pivotal Phase III study conducted with an endpoint of immunogenic superiority, Corbevax demonstrated superior immune response in comparison with Covishield vaccine when assessed for Neutralizing Antibody (nAb) Geometric Mean Titers (GMT) against the Ancestral-Wuhan strain and the globally dominant Delta variant, the release said.

"Our scientists at Texas Children’s Hospital and Baylor College of Medicine are thrilled to help in the development of this vaccine, possibly the first covid vaccine specifically designed for global health," Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children’s Hospital Centre for Vaccine Development said. 

-With PTI Inputs

Advertisement

Outlook Newsletters

Advertisement
Advertisement
Advertisement

More from

Read More from Outlook

Lament Of Separation: Songs Of Habba Khatun, Last Queen Of Kashmir, Still Echo In Valley

Lament Of Separation: Songs Of Habba Khatun, Last Queen Of Kashmir, Still Echo In Valley

In happy times and sad, Habba Khatun’s sensuous songs make both young and old emotional. With the never-ending conflict bringing tragedies to every doorstep, Habba’s lyrics of separation amplify their mourning.

How Indian Laws Govern People’s Right To Love And Live

How Indian Laws Govern People’s Right To Love And Live

In India, only those relationships between a man and a woman are considered to be legitimate when there is a marriage between the two.

Kohli Quits Test Captaincy, Leaves Leadership Vacuum

Kohli Quits Test Captaincy, Leaves Leadership Vacuum

Virat Kohli, 33, had recently stepped down as India's T20I captain and was subsequently removed as the ODI captain.

UP Elections 2022: How Congress Is Harnessing Power Of 'Persecuted' Women To Counter BJP

UP Elections 2022: How Congress Is Harnessing Power Of 'Persecuted' Women To Counter BJP

A Mahila Congress leader, who is the face of the ‘Ladki Hoon, Lad Sakti Hoon’ campaign, however, has accused the party of anti-women bias after she was denied a ticket.

Advertisement